abc biopply in chip Multi Organoid Systems

abc biopply's Services to de-risk your Drug Development Projects

nach unten

abc biopply Drug Efficacy Services

Tumour Relaps Assays, Viability Assays, Cytotoxicity Assays, Cell Viability Assays, and many more...

nach unten

3D CoSeedis™

Easy Mass Production of Uniform and Homogenous Spheroids / Organoids for Predictive Disease Modelling

nach unten

abc biopply Histology Services

In chip Immunohistochemistry, Immunofluorescence and Histology

nach unten

abc biopply 3D Cell Culture Services

Design and Set-up of Preclinical Desease Models and Complex 3D Cell Culture Systems

nach unten

abc biopply - Preclinical Study Models and Services to De-Risk Drug Development

The process for commercializing preclinically confirmed drugs currently has a success rate of only about 12%.

abc biopply is a specialist for advanced solutions in preclinical disease models and drug discovery. The company has pioneered a unique portfolio of 3D tissue imaging and analysis assays enabling the easy and reliable generation of quantitative datasets from tissues and cells. Based on the proprietary 3D CoSeedis™ multi-organoid technology the company has boosted the relevance of in vitro testing to the ex vivo level.

The related CRO services support pharmaceutical and biotech companies to improve the predictiveness of their preclinical models and to de-risk their drug discovery processes.

Advantages at a glance

  • Advanced predictiveness of preclinical disease models and drug development
  • Provide excellent measurement quality of the conditions of environmentally-mediated drug resistance
  • Enabling a rapid pre-selection of compounds
  • abc biopply in-chip study models fully comply with FDA requirements for a micro physiological system
  • Elimination of discovery load in traditional animal models
  • Time- and cost-efficient alternative to conventional variants
  • 3R: enabling animal free testing

The 3D CoSeedis™ system is a great tool to generate standardized 3D cultures of patient derived ovarian cancer cells. Through this system we were able to quickly implement an ex vivo culture system of patient derived cells with a tremendous potential to be applied in personalized medicine.

Dr. Ricardo Coelho
Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel, Switzerland

So far, I can tell that we are very satisfied. We tried several other tools for spheroid culturing, but this is by far the easiest to handle.

Alessandra Cereghetti
PhD Student, Dept. of Mol. Mech. of Disease, University of Zurich, Switzerland

3D CoSeedis™ convinces through its innovative modularity that allows us to grow cells in 3D aggregates that normally wouldn’t do so. It either supports aggregation through its unique topography or by the ability to grow feeder cells in a physically separated, distant manner. When investigating the response rate of various tumour cells to radiation, the 3D CoSeedis™ System allows us the flexibility and statistics that we need in experiments.

Dr. Peter Frost
CEO and Owner of PeloBiotech GmbH, Germany

3D CoSeedis™ Productvideo

Contact us